Before everyone starts to panic, let's remember that this company managed to get Abbott Labs to license the technology. Yes, Abbott "only" payed a $250k upfront, but they have also assigned lab personnel, lab time, and equipment to the task of integrating RECAF onto ARCHITECT and further exploring it. They also have plans to publish, as reported by HALF-FULL's response from the Abbott spokesman. I find it VERY, VERY hard to believe that Abbott Labs's blind sample verification process could be duped by Moro...so that relationship adds tremendously to Moro's credibility. I have also posted a lot of evidence from Abbott's website that shows they don't go around signing on any little marker that comes around. To the contrary, they seem to have an extremely selective licensing process.
There are other factors that add tremendously to Moro's credibility, including the verification in Japan/Europe, Dr. Gold's involvement, and Moro's publishing of his full data set at the ISOBM last year.
The penny stock scams that I have encountered and read about do not have even close to that kind of body of evidence that points to their "credibility."
Goodman...As for the article you posted, BOCX only fits a few of the points and to tell you the truth some of them are jaw-droppingly ridiculous. Like the statement that one should altogether avoid a public company solely because it is based in Vancouver. Vancouver might be a hotspot of penny stock fraud, but it is also a hotspot of biotechnology. San Diego is also considered a hotspot of biotechnology. So to not invest in a biotech stock from either of those two cities, as the article recommends, is TOTALLY RIDICULOUS.
DISCLAIMER: NEVER ASSUME INFO ON MESSAGE BOARDS TO BE ACCURATE. ALWAYS DO YOUR OWN DUE DILIGENCE. DON'T BUY STOCK BASED ON THIS POST OR ANY OTHER POST. I OWN A LONG POSITION IN THIS STOCK AND THEREFORE I AM BIASED.
